However, our study revealed for the first time that ASPP2 has specific effect on the composition of omega-3 PUFAs despite no change in total fatty acid content, a key mechanism by which ASPP2 triggers the initiation of NAFLD. This evidence concerns the gene TP53BP2 and metabolic dysfunction-associated steatotic liver disease.